申请人:SAGE THERAPEUTICS, INC.
公开号:US20160108080A1
公开(公告)日:2016-04-21
Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein-, R
1
, R
2
, R
3a
, R
3b
, R
4a
, R
4b
, R
5
, R
6
, and R
7
are as defined herein. Such compounds are contemplated useful NI for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
本文提供了19-去氢C3,3-二取代C21-吡唑基类固醇的化学式(I),以及其药学上可接受的盐;其中,R1、R2、R3a、R3b、R4a、R4b、R5、R6和R7的定义如本文所述。这些化合物被认为对预防和治疗各种与中枢神经系统相关的疾病有用,例如治疗睡眠障碍、情绪障碍、精神分裂症谱系障碍、惊厥性疾病、记忆和/或认知障碍、运动障碍、人格障碍、自闭症谱系障碍、疼痛、创伤性脑损伤、血管疾病、物质滥用障碍和/或戒断综合征以及耳鸣具有预防和治疗作用。